- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-4889
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance ; volume:11 ; number:11 ; day:2 ; month:11 ; year:2020 ; pages:1-11 ; date:11.2020
Cell death & disease ; 11, Heft 11 (2.11.2020), 1-11, 11.2020
- Creator
-
Kapoor, Isha
Bodo, Juraj
Hill, Brian T.
Hsi, Eric D.
Almasan, Alexandru
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41419-020-03144-y
- URN
-
urn:nbn:de:101:1-2020121518550445248501
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kapoor, Isha
- Bodo, Juraj
- Hill, Brian T.
- Hsi, Eric D.
- Almasan, Alexandru
- SpringerLink (Online service)
Other Objects (12)
Targeting CD22 for B-cell hematologic malignancies
Enhancing cell death in B-cell malignancies through targeted inhibition of Bcl-3
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003
Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy
BCL-2 as therapeutic target for hematological malignancies
Targeting immune checkpoints in hematological malignancies
Targeting splicing for hematological malignancies therapy
Mechanisms of B-cell antigen receptor activation in lymphoid malignancies
Aberrant cell cycle regulatory ubiquitin networks in B-cell malignancies
Targeting posttranslational modifications to treat hematological malignancies
Targeting self-renewal pathways in myeloid malignancies
Targeting hypoxia in solid and haematological malignancies
Targeting CD22 for B-cell hematologic malignancies
Enhancing cell death in B-cell malignancies through targeted inhibition of Bcl-3
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003
Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy
BCL-2 as therapeutic target for hematological malignancies
Targeting immune checkpoints in hematological malignancies
Targeting splicing for hematological malignancies therapy
Mechanisms of B-cell antigen receptor activation in lymphoid malignancies
Aberrant cell cycle regulatory ubiquitin networks in B-cell malignancies
Targeting posttranslational modifications to treat hematological malignancies
Targeting self-renewal pathways in myeloid malignancies
Targeting hypoxia in solid and haematological malignancies
Targeting CD22 for B-cell hematologic malignancies
Enhancing cell death in B-cell malignancies through targeted inhibition of Bcl-3
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003
Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy
BCL-2 as therapeutic target for hematological malignancies
Targeting immune checkpoints in hematological malignancies
Targeting splicing for hematological malignancies therapy
Mechanisms of B-cell antigen receptor activation in lymphoid malignancies
Aberrant cell cycle regulatory ubiquitin networks in B-cell malignancies
Targeting posttranslational modifications to treat hematological malignancies
Targeting self-renewal pathways in myeloid malignancies